Neose Technologies, Inc. today identified Factors VIIa, VIII and IX as the three
proteins that are the subject of license agreements it entered into with Novo
Nordisk A/S in November 2003. "We continue to be pleased with the progress
of our collaboration with Novo Nordisk to develop long-acting, GlycoPEGylated
versions of these proteins. We are excited about the benefits our GlycoPEGylation
technology may provide to Novo in broadening their haemostasis product portfolio,"
said George J. Vergis, Ph.D., Neose president and chief executive officer.